Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

Cardiovascular considerations in patients undergoing gastrointestinal endoscopy.

A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C.

Potentiation of acetaminophen hepatotoxicity by phenytoin, leading to liver transplantation.

Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT.

Cholelithiasis and choledocholithiasis after sequential cytarabine and asparaginase.

NO-NSAIDs and cancer: promising novel agents.

Effect on treatment outcome of coinfection with SEN viruses in patients with hepatitis C.

Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone.

Percutaneous cholecystoduodenostomy: a case report.

Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States.

Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels.

Peritoneal-urinary drainage for treatment of refractory ascites: a pilot study.

Pruritus in chronic hepatitis C: association with high serum bile acids, advanced pathology, and bile duct abnormalities.

The breakthrough phenomenon during alpha-interferon therapy of chronic hepatitis C: incidence, management, and outcome.